ErbB2 (HER-2) Monoclonal Antibody (3B5), Biotin | Invitrogen MA5-13672 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

ErbB2 (HER-2) Monoclonal Antibody (3B5), Biotin

catalog :

MA5-13672

quantity :

500 µL

price :

US 496.00

clonality :

monoclonal

host :

mouse

conjugate :

biotin

clone name :

3B5

reactivity :

hamsters, human, mouse, rat, chicken, cat

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry

more info or order :

Invitrogen product webpage

citations: 59

Published Application/Species/Sample/Dilution	Reference
ELISA; human	Silva J, Cárdenas R, Quiróz A, Sánchez V, Lozano L, Pérez N, et al. Impedance spectroscopy assisted by magnetic nanoparticles as a potential biosensor principle for breast cancer cells in suspension. Physiol Meas. 2014;35:931-41 pubmed publisher
western blot; human; 1:500	Janjigian Y, Viola Villegas N, Holland J, Divilov V, Carlin S, Gomes Dagama E, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013;54:936-43 pubmed publisher
western blot; human	Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, et al. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci Rep. 2013;3:1106 pubmed publisher
immunohistochemistry; human	Hechtman J, Polydorides A. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med. 2012;136:691-7 pubmed publisher
immunocytochemistry; human immunohistochemistry; human western blot; human	Cortés M, Cariaga Martínez A, Lobo M, Martín Orozco R, Motiño O, Rodríguez Ubreva F, et al. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis. 2012;33:1169-77 pubmed publisher
immunohistochemistry; human; 1:400	Yigit S, Pehlivan F, Evcim G, Etit D. Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases. Pathol Res Pract. 2012;208:147-50 pubmed publisher
immunohistochemistry; human; 1:200	El Gendi S, Mostafa M, El Gendi A. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res. 2012;18:459-69 pubmed publisher
western blot; mouse; 1:1000	de Assis S, Warri A, Benitez C, Helferich W, Hilakivi Clarke L. Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression. Cancer Prev Res (Phila). 2011;4:1436-48 pubmed publisher
immunoprecipitation; human	DeFazio Eli L, Strommen K, Dao Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res. 2011;13:R44 pubmed publisher
immunohistochemistry; human; 1:1	Abdelzaher E, El Gendi S, Yehya A, Gowil A. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg. 2011;25:707-13 pubmed publisher
immunocytochemistry; rat	Hoa N, Ge L, Kuznetsov Y, McPherson A, Cornforth A, Pham J, et al. Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes. J Immunol. 2010;185:4793-803 pubmed publisher
immunoprecipitation; human western blot; human	Bollig Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux C, Ethier S. HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res. 2010;70:7862-73 pubmed publisher
immunohistochemistry; human; 1:2000	Rygiel A, Milano F, ten Kate F, Bergman J, Krishnadath K. Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus. J Oncol. 2010;2010:382582 pubmed publisher
immunohistochemistry; human; 1:300	Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen E, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010;116:3330-7 pubmed publisher
immunohistochemistry; human	Norell H, Poschke I, Charo J, Wei W, Erskine C, Piechocki M, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010;8:53 pubmed publisher
western blot; mouse	Park S, Lee K, Ju J, Kim J, Noh D, Lee T, et al. Protein expression profiling of primary mammary epithelial cells derived from MMTV-neu mice revealed that HER2/NEU-driven changes in protein expression are functionally clustered. IUBMB Life. 2010;62:41-50 pubmed publisher
immunoprecipitation; mouse western blot; mouse	Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis C, et al. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2010;29:325-34 pubmed publisher
immunohistochemistry; cat	Misirlioglu D, Nak D, Ozyigit M, Nak Y, Akkoc A. HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats. J Feline Med Surg. 2009;11:885-8 pubmed publisher
immunohistochemistry; chicken; 1 ug/ml	Hakim A, Barry C, Barnes H, Anderson K, Petitte J, Whitaker R, et al. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila). 2009;2:114-21 pubmed publisher
immunoprecipitation; human western blot; mouse	Lewis Phillips G, Li G, Dugger D, Crocker L, Parsons K, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280-90 pubmed publisher
immunohistochemistry; human; 1:300	Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, et al. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008;16:530-4 pubmed publisher
western blot; mouse; 1:2.000	Strumane K, Rygiel T, van der Valk M, Collard J. Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice. J Cancer Res Clin Oncol. 2009;135:69-80 pubmed publisher
immunohistochemistry; human flow cytometry; mouse	Piechocki M. A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents. BMC Cancer. 2008;8:119 pubmed publisher
immunocytochemistry; human; 1:200	Katsumi Y, Kuwahara Y, Tamura S, Kikuchi K, Otabe O, Tsuchiya K, et al. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. Clin Cancer Res. 2008;14:1192-9 pubmed publisher
immunohistochemistry; human; 1:250	Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E. Primary neuroendocrine carcinoma of the breast: a case report. Tumori. 2007;93:496-8 pubmed
immunohistochemistry; human; 1:3000	Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65 pubmed
western blot; human	Martín Orozco R, Almaraz Pro C, Rodríguez Ubreva F, Cortés M, Ropero S, Colomer R, et al. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia. 2007;9:614-24 pubmed
western blot; human; 0.1 ug/ml	Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, et al. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins. 2008;70:938-49 pubmed
immunohistochemistry; hamsters; 1:150	Vairaktaris E, Moulavassili P, Loukeri S, Spyridonidou S, Yapijakis C, Vassiliou S, et al. Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis. J Musculoskelet Neuronal Interact. 2007;7:185-90 pubmed
immunocytochemistry; rat western blot; rat	Zscheppang K, Liu W, Volpe M, Nielsen H, Dammann C. ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells. Am J Physiol Lung Cell Mol Physiol. 2007;293:L429-35 pubmed
immunohistochemistry; human	Tokatli F, Alas R, Altaner S, Pala F, Uygun K, Uzal C, et al. [An analysis of genetic transmission in a father and son with osteosarcoma]. Acta Orthop Traumatol Turc. 2006;40:407-10 pubmed
western blot; human; 1:400	Half E, Sun Y, Sinicrope F. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett. 2007;251:237-46 pubmed
immunohistochemistry; human; 1:100	Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva F, et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2007;109:496-501 pubmed
immunohistochemistry; human	Schmidt M, Tollenaar R, de Kemp S, Broeks A, Cornelisse C, Smit V, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25:64-9 pubmed
immunohistochemistry; mouse	Shyamala G, Chou Y, Cardiff R, Vargis E. Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res. 2006;66:10391-8 pubmed
immunoprecipitation; mouse immunocytochemistry; mouse	Zscheppang K, Korenbaum E, Bueter W, Ramadurai S, Nielsen H, Dammann C. ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. Pediatr Pulmonol. 2006;41:1205-12 pubmed
western blot; mouse; 1:1000	Qu S, Rinehart C, Wu H, Wang S, Carter B, Xin H, et al. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis. 2006;44:477-86 pubmed
immunohistochemistry; human; 1:100	Karg A, Dinç Z, Basok O, Ucvet A. MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC). Pathol Res Pract. 2006;202:577-83 pubmed
western blot; human; 1:200	Hansen M, Roehm P, Chatterjee P, Green S. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia. 2006;53:593-600 pubmed
immunohistochemistry; mouse western blot; human	Khalili P, Arakelian A, Chen G, Singh G, Rabbani S. Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene. 2005;24:6657-66 pubmed
western blot; human; 1:200	Stewart L, Lyles B, Lin M, Weigel N. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005;97:37-46 pubmed
immunohistochemistry; rat; 1:600 western blot; rat	Price Schiavi S, Andrechek E, Idris N, Li P, Rong M, Zhang J, et al. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol. 2005;203:44-53 pubmed
	Huang W, REINHOLZ M, Weidler J, Yolanda L, Paquet A, Whitcomb J, et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol. 2010;134:303-11 pubmed publisher
	Zinser G, Welsh J. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis. 2004;25:2361-72 pubmed
	Lenferink A, Magoon J, Cantin C, O Connor McCourt M. Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition. Breast Cancer Res. 2004;6:R514-30 pubmed
	Half E, Broaddus R, Danenberg K, Danenberg P, Ayers G, Sinicrope F. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004;108:540-8 pubmed
	Middleton L, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98:1055-60 pubmed
	Simpson R, Prasad A, Lewis J, Skalova A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27:1070-9 pubmed
	Nielsen U, Cardone M, Sinskey A, MacBeath G, Sorger P. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci U S A. 2003;100:9330-5 pubmed
	Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, et al. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch. 2003;442:322-8 pubmed
	Dakappagari N, Pyles J, Parihar R, Carson W, Young D, Kaumaya P. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol. 2003;170:4242-53 pubmed
	Lucchese A, Stevanovic S, Sinha A, Mittelman A, Kanduc D. Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope. Peptides. 2003;24:193-7 pubmed
	Davis D, Buchholz T, Hess K, Sahin A, Valero V, McConkey D. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003;9:955-60 pubmed
	Verschraegen C, Hu W, Du Y, Mendoza J, Early J, Deavers M, et al. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003;9:845-52 pubmed
	van Eeden S, Quaedvlieg P, Taal B, Offerhaus G, Lamers C, van Velthuysen M. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol. 2002;33:1126-32 pubmed
	Mittelman A, Lucchese A, Sinha A, Kanduc D. Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome. Int J Cancer. 2002;98:741-7 pubmed
	Half E, Tang X, Gwyn K, Sahin A, Wathen K, Sinicrope F. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002;62:1676-81 pubmed
	Murillo H, Schmidt L, Tindall D. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. Cancer Res. 2001;61:7408-12 pubmed
	Moasser M, Basso A, Averbuch S, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001;61:7184-8 pubmed

image

image 1 :

image 2 :

image 3 :

product information

Product Type :

Antibody

Product Name :

ErbB2 (HER-2) Monoclonal Antibody (3B5), Biotin

Catalog # :

MA5-13672

Quantity :

500 µL

Price :

US 496.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human, Mouse

Applications :

Immunohistochemistry: 1:1,000-1:1,500, Immunoprecipitation: 1:25, Western Blot: 1 µg/mL

Species :

Human, Mouse

Clone :

3B5

Isotype :

IgG1

Storage :

4° C

Description :

ErbB2 (HER2) is a receptor tyrosine kinase that is overexpressed in some breast tumors. Herceptin, used in treatment of metastatic Her2-positive cancer, is monoclonal antibody targeting this kinase.

Immunogen :

A synthetic peptide from the C-terminus of human c-erbB-2 protein. This Sequence Is Identical In Rat Neu Protein.

Format :

Liquid

Applications w/Dilutions :

Immunohistochemistry: 1:1,000-1:1,500, Immunoprecipitation: 1:25, Western Blot: 1 µg/mL

Aliases :

avian erythroblastosis oncogene B 2; Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); CD antigen CD340; CD340; c-erb B2/neu protein; c-erbB2; C-erbB-2; c-neu; epidermal growth factor receptor-related protein; erbb 2; ERBB2; erb-b2; Erbb-2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; erb-b2 receptor tyrosine kinase 2; her 2; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; Kiaa3023; metas; Metastatic lymph node gene 19 protein; mKIAA3023; MLN 19; MLN19; NEU; Neu oncogene; NEU proto-oncogene; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; p185neu; phospho ErbB2; proto-oncogene c-ErbB-2; Proto-oncogene Neu; receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)

more info or order :

Invitrogen product webpage